Biofrontera (BFRI) Q4 2024 earnings summary

Executive summary

• Achieved record annual sales of $37.3 million in 2024, up 9.5% year-over-year and 18.5% in Q4, driven by Ameluz sales, RhodoLED XL lamp launch, and strategic initiatives.

• Placed 100 RhodoLED XL lamps since June 2024, supporting Ameluz PDT expansion and obtained FDA approval for expanded Ameluz use.

• Advanced clinical pipeline with positive phase 3 results for new indications and significant progress in phase 2 and 3 studies.

• Restructured agreements with former parent, reducing Ameluz transfer price from 50% to 25% for 2024-2025.

Financial highlights

• Q4 2024 revenue was $12.6 million, up 18.5% year-over-year; full-year revenue reached $37.3 million, up 9.5%.

• Q4 net loss was $1.4 million ($0.19/share) vs. net income of $3.5 million in Q4 2023, due to a prior-year legal settlement gain.

• Full-year net loss was $17.8 million ($3.22/share), improved from $20.1 million loss in 2023.

• Adjusted EBITDA for 2024 was negative $15.3 million, improved from negative $19.5 million in 2023.

• Cash and equivalents at year-end 2024 were $5.9 million, up from $1.3 million at end of 2023.

Outlook and guidance

• Management expects another record sales year in 2025, supported by expanded product use, label extensions, and clinical progress.

• SG&A and R&D expenses are expected to remain stable in 2025.

• Anticipates improved gross margins in 2025 due to lower transfer pricing.

• Strategic focus for 2025 includes supporting current customers and expanding the customer base.